EMAIL THIS PAGE TO A FRIEND

Tissue engineering. Part A

Experimental and computational investigation of the effect of hydrophobicity on aggregation and osteoinductive potential of BMP-2-derived peptide in a hydrogel matrix.


PMID 25051457

Abstract

An attractive approach to reduce the undesired side effects of bone morphogenetic proteins (BMPs) in regenerative medicine is to use osteoinductive peptide sequences derived from BMPs. Although the structure and function of BMPs have been studied extensively, there is limited data on structure and activity of BMP-derived peptides immobilized in hydrogels. The objective of this work was to investigate the effect of concentration and hydrophobicity of the BMP-2 peptide, corresponding to residues 73-92 of the knuckle epitope of BMP-2 protein, on peptide aggregation and osteogenic differentiation of human mesenchymal stem cells encapsulated in a polyethylene glycol (PEG) hydrogel. The peptide hydrophobicity was varied by capping PEG chain ends with short lactide segments. The BMP-2 peptide with a positive index of hydrophobicity had a critical micelle concentration (CMC) and formed aggregates in aqueous solution. Based on simulation results, there was a slight increase in the concentration of free peptide in solution with 1000-fold increase in peptide concentration. The dose-osteogenic response curve of the BMP-2 peptide was in the 0.0005-0.005 mM range, and osteoinductive potential of the BMP-2 peptide was significantly less than that of BMP-2 protein even at 1000-fold higher concentrations, which was attributed to peptide aggregation. Further, the peptide or PEG-peptide aggregates had significantly higher interaction energy with the cell membrane compared with the free peptide, which led to a higher nonspecific interaction with the cell membrane and loss of osteoinductive potential. Conjugation of the BMP-2 peptide to PEG increased CMC and osteoinductive potential of the peptide whereas conjugation to lactide-capped PEG reduced CMC and osteoinductive potential of the peptide. Experimental and simulation results revealed that osteoinductive potential of the BMP-2 peptide is correlated with its CMC and the free peptide concentration in aqueous medium and not the total concentration.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

CDS002784
1H-1,2,3-Benzotriazol-7-ol, AldrichCPR
C6H5N3O
39405
4-(Dimethylamino)pyridine, purum, ≥98.0% (NT)
C7H10N2
632791
4-Hydroxy-1H-benzotriazole, 97%
C6H5N3O
147230
Acrylic acid, anhydrous, contains 200 ppm MEHQ as inhibitor, 99%
C3H4O2
549797
Acryloyl chloride, 97.0%, contains <210 ppm MEHQ as stabilizer
C3H3ClO
A24109
Acryloyl chloride, ≥97%, contains ~400 ppm phenothiazine as stabilizer
C3H3ClO
497355
Calcium hydride, powder, 99.99% trace metals basis
H2Ca
558257
Calcium hydride, 99.9% trace metals basis
H2Ca
208027
Calcium hydride, reagent grade, 95% (gas-volumetric)
H2Ca
213268
Calcium hydride, powder, 0-2 mm, reagent grade, ≥90% (gas-volumetric)
H2Ca
21170
Calcium hydride, purum p.a., ≥97.0% (gas-volumetric), powder
H2Ca
03440
N-Ethyldiisopropylamine, BASF quality, ≥98.0%
C8H19N
411027
Piperidine, ≥99.5%, purified by redistillation
C5H11N
104094
Piperidine, ReagentPlus®, 99%
C5H11N
76046
Piperidine, analytical standard
C5H11N
80642
Piperidine, purum, ≥96.0% (GC/T)
C5H11N
W290807
Piperidine, ≥99%, FCC
C5H11N
80645
Piperidine solution, for peptide synthesis, 20% in DMF
C5H11N
233781
Triisopropylsilane, 98%
C9H22Si
Y0001099
Valaciclovir impurity G, European Pharmacopoeia (EP) Reference Standard
C7H10N2
1707894
Valacyclovir Related Compound G, United States Pharmacopeia (USP) Reference Standard
C7H10N2